



TORRENT PHARMACEUTICALS LIMITED

Regd. Office : Torrent House, Off Ashram Road, Ahmedabad-380 009

UNAUDITED CONSOLIDATED FINANCIAL RESULTS

[Rs. in Lacs except per share data]

| PARTICULARS | UNAUDITED | | | | | AUDITED |
|--|---------------|--------------|--------------|-------------------|---------------|---------------|
| | QUARTER ENDED | | | NINE MONTHS ENDED | | YEAR ENDED |
| | 31-Dec-2011 | 30-Sep-2011 | 31-Dec-2010 | 31-Dec-2011 | 31-Dec-2010 | 31-Mar-2011 |
| Sales (See note 3) | 68853 | 67146 | 56511 | 198490 | 166215 | 216062 |
| Less: Excise and similar duties collected | 1299 | 1370 | 1029 | 3821 | 2999 | 3865 |
| Net Sales | 67554 | 65776 | 55482 | 194669 | 163216 | 212197 |
| Other Operating Income | 2105 | 2557 | 2271 | 8055 | 6788 | 10451 |
| Total Income | 69659 | 68333 | 57753 | 202724 | 170004 | 222648 |
| Expenditure | | | | | | |
| (Increase) / Decrease in Stock in Trade and Work in Progress | (73) | 209 | (3640) | (1338) | (10108) | (12627) |
| Consumption of Raw / Packing Material | 16525 | 15952 | 15237 | 48107 | 44435 | 58469 |
| Purchase of Traded Goods | 5776 | 6050 | 6111 | 17260 | 18108 | 23811 |
| Employees Cost | 11992 | 11607 | 9792 | 34747 | 28925 | 38952 |
| Research and Development Expenses | 3492 | 3171 | 3479 | 9960 | 9917 | 13884 |
| Depreciation and Amortization | 1970 | 2007 | 1613 | 5996 | 4582 | 6256 |
| Other Expenditure | 19799 | 17277 | 15275 | 52460 | 44262 | 59239 |
| Total Expenditure | 59481 | 56273 | 47867 | 167192 | 140121 | 187984 |
| Profit from Operations before Other Income and Interest | 10178 | 12060 | 9886 | 35532 | 29883 | 34664 |
| Other Income | 234 | 425 | 182 | 903 | 653 | 809 |
| Profit Before Interest | 10412 | 12485 | 10068 | 36435 | 30536 | 35473 |
| Net Borrowing Cost | 15 | 293 | 345 | 713 | 927 | 1206 |
| Profit from Ordinary Activities before tax | 10397 | 12192 | 9723 | 35722 | 29609 | 34267 |
| Tax expense | 2006 | 2115 | 2032 | 6995 | 6877 | 7251 |
| Net Profit from Ordinary Activities after tax before minority interest | 8391 | 10077 | 7691 | 28727 | 22732 | 27016 |
| Minority interest | 73 | 78 | - | 158 | - | (0.41) |
| Net Profit after minority interest | 8318 | 9999 | 7691 | 28569 | 22732 | 27017 |
| Paid-up Equity Share Capital (Face value of Rs.5) | 4231 | 4231 | 4231 | 4231 | 4231 | 4231 |
| Reserves excluding Revaluation Reserves | - | - | - | - | - | 98010 |
| Basic and Diluted EPS for the period | 9.83 | 11.81 | 9.09 | 33.76 | 26.87 | 31.93 |
| Public shareholding | | | | | | |
| Number of shares | 24109500 | 24109500 | 24109500 | 24109500 | 24109500 | 24109500 |
| Percentage of shareholding | 28.49% | 28.49% | 28.49% | 28.49% | 28.49% | 28.49% |
| Promoters and promoter group shareholding | | | | | | |
| (a)Pledged/Encumbered | | | | | | |
| - Number of shares | Nil | Nil | Nil | Nil | Nil | Nil |
| - Percentage of shares (as a % of the total shareholding of promoter and promoter group) | Nil | Nil | Nil | Nil | Nil | Nil |
| - Percentage of shares (as a % of the total share capital of the company) | Nil | Nil | Nil | Nil | Nil | Nil |
| (b)Non-encumbered | | | | | | |
| - Number of shares | 60501860 | 60501860 | 60501860 | 60501860 | 60501860 | 60501860 |
| - Percentage of shares (as a % of the total shareholding of promoter and promoter group) | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| - Percentage of shares (as a % of the total share capital of the company) | 71.51% | 71.51% | 71.51% | 71.51% | 71.51% | 71.51% |

Notes :

- The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 23-Jan-2012. The statutory auditors have carried out a limited review of the results for the quarter and nine months ended 31-Dec-2011. There is no adverse observation in the limited review report on this statement of financial results.
- The statement of financial results consolidate the financial results of fifteen wholly owned subsidiaries and two partnership firms with that of the Company.
- The Company operates a solitary business segment viz. pharmaceuticals, comprising mainly manufacture of branded formulations. A further breakdown of pharmaceutical sales is given below :

Rs. in Lacs

| PARTICULARS | UNAUDITED | | | | | | AUDITED |
|----------------------------------|---------------|--------------|------------|-------------------|---------------|------------|---------------|
| | QUARTER ENDED | | | NINE MONTHS ENDED | | | YEAR ENDED |
| | 31-Dec-2011 | 31-Dec-2010 | Growth% | 31-Dec-2011 | 31-Dec-2010 | Growth% | 31-Mar-2011 |
| (A) Sales in India | | | | | | | |
| Branded Business | 23021 | 21379 | 8% | 71512 | 65948 | 8% | 84163 |
| Contract Manufacture | 6087 | 5938 | 3% | 17734 | 15992 | 11% | 21385 |
| Others | 139 | 39 | - | 361 | 236 | - | 356 |
| Total Sales in India | 29247 | 27356 | 7% | 89607 | 82176 | 9% | 105904 |
| (B) Sales outside India | 39606 | 29155 | 36% | 108883 | 84039 | 30% | 110158 |
| Total Sales (A+B) | 68853 | 56511 | 22% | 198490 | 166215 | 19% | 216062 |
| Less : Excise and similar duties | 1299 | 1029 | - | 3821 | 2999 | - | 3865 |
| Net Sales | 67554 | 55482 | 22% | 194669 | 163216 | 19% | 212197 |

- With effect from 01-Apr-2011, the Company has adopted Accounting Standard 30 (AS 30) "Financial Instruments: Recognition and Measurement" with respect to accounting for derivatives, to the extent adoption does not conflict with existing mandatory accounting standards and other authoritative pronouncements, Company Law and other regulatory requirements. This adoption has resulted in change in accounting policy followed by the Company in respect of derivatives. As per requirement of the transitional provisions in AS 30, Rs. 129 lacs, being the difference between the carrying value and fair value of the derivatives, as on 01-Apr-2011 has been credited to the General Reserve Account. Further, consequent to this, for the current quarter and for the nine months ended on 31-Dec-2011, net foreign exchange loss is lower by Rs. 3794 lacs and Rs. 5949 lacs and net profit is higher by Rs. 3044 lacs and Rs. 4772 lacs respectively.
- The Board of Directors at its meeting held on 23-Jan-2012, declared an interim equity dividend of Rs. 6.00 for the year 2011-12 per equity share of Rs. 5.00 each fully paid up. The aggregate amount of interim equity dividend proposed to be distributed is Rs. 5900 lacs including tax on distributed profits of Rs. 824 lacs.
- During the quarter, one investor complaint was received and resolved. No complaints were pending either at the beginning or at the end of the quarter.
- The figures for the comparative periods have been regrouped, wherever necessary, to make them comparable with the figures for the current periods.
- Summary details of stand-alone audited financial results of Torrent Pharmaceuticals Limited :

Rs. in Lacs

| PARTICULARS | QUARTER ENDED | | | NINE MONTHS ENDED | | YEAR ENDED |
|------------------------------|---------------|-------------|-------------|-------------------|-------------|-------------|
| | 31-Dec-2011 | 30-Sep-2011 | 31-Dec-2010 | 31-Dec-2011 | 31-Dec-2010 | 31-Mar-2011 |
| Net Sales & Operating Income | 51840 | 50790 | 45956 | 153082 | 135973 | 177819 |
| Profit before tax | 7975 | 8879 | 8054 | 29363 | 30476 | 35822 |
| Profit after tax | 6151 | 7023 | 6595 | 23118 | 24640 | 29086 |

- The standalone audited financial results for the quarter and nine months ended 31-Dec-2011 are available on the Company's website at www.torrentpharma.com.

For TORRENT PHARMACEUTICALS LIMITED

Place : Indrad, Mehsana
Date : 23-Jan-2012

sd/-
SAMIR MEHTA
Executive Vice Chairman

... Visit us at www.torrentpharma.com...